Skip to main content
editorial
. 2018 Jun 14;119(1):1–3. doi: 10.1038/s41416-018-0122-x

Fig. 1.

Fig. 1

TGFβ shuts the door on T cells. Cancer associated fibroblasts (CAF) release TGFβ to exclude T cells from colorectal and metastatic urothelial cancer tumours. Co-targeting PD-L1 and TGFβ (via anti-TGFβ, TGFβR-inhibitor or TGFβ-traps) may overcome T cell exclusion and immune checkpoint function to convert excluded tumours to inflamed tumours and thus broaden the effectiveness of cancer immunotherapy